Literature DB >> 17446349

Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV.

Sarah C Darby1, Sau Wan Kan, Rosemary J Spooner, Paul L F Giangrande, Frank G H Hill, Charles R M Hay, Christine A Lee, Christopher A Ludlam, Michael Williams.   

Abstract

Since the 1970s, mortality in the hemophilia population has been dominated by human immunodeficiency virus (HIV) and few reports have described mortality in uninfected individuals. This study presents mortality in 6018 people with hemophilia A or B in the United Kingdom during 1977 to 1998 who were not infected with HIV, with follow-up until January 1, 2000. Given disease severity and factor inhibitor status, all-cause mortality did not differ significantly between hemophilia A and hemophilia B. In severe hemophilia, all-cause mortality did not change significantly during 1977 to 1999. During this period, it exceeded mortality in the general population by a factor of 2.69 (95% confidence interval [CI]: 2.37-3.05), and median life expectancy in severe hemophilia was 63 years. In moderate/mild hemophilia, all-cause mortality did not change significantly during 1985 to 1999, and median life expectancy was 75 years. Compared with mortality in the general population, mortality from bleeding and its consequences, and from liver diseases and Hodgkin disease, was increased, but for ischemic heart disease it was lower, at only 62% (95% CI: 51%-76%) of general population rates, and for 14 other specific causes it did not differ significantly from general population rates. There was no evidence of any death from variant Creutzfeldt-Jakob disease or from conditions that could be confused with it.

Entities:  

Mesh:

Year:  2007        PMID: 17446349     DOI: 10.1182/blood-2006-10-050435

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  100 in total

1.  Participation of people with haemophilia in clinical trials of new treatments: an investigation of patients' motivations and existing barriers.

Authors:  Séverine Henrard; Niko Speybroeck; Cedric Hermans
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

2.  Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.

Authors:  Margaret V Ragni
Journal:  Expert Rev Hematol       Date:  2011-10       Impact factor: 2.929

3.  Improved coagulation and haemostasis in haemophilia with inhibitors by combinations of superFactor Va and Factor VIIa.

Authors:  Vikas Bhat; Annette von Drygalski; Andrew J Gale; John H Griffin; Laurent O Mosnier
Journal:  Thromb Haemost       Date:  2015-10-15       Impact factor: 5.249

Review 4.  Current concepts in the management of stable ischemic heart disease and acute coronary syndrome in patients with hemophilia.

Authors:  Ahmad Y Jabbar; Hassan Baydoun; Maissaa Janbain; Keith C Ferdinand
Journal:  Ann Transl Med       Date:  2018-08

5.  Risk factors for inhibitor formation in haemophilia: a prevalent case-control study.

Authors:  M V Ragni; O Ojeifo; J Feng; J Yan; K A Hill; S S Sommer; M N Trucco; D J Brambilla
Journal:  Haemophilia       Date:  2009-06-26       Impact factor: 4.287

6.  Coronary atherosclerosis and cardiovascular mortality in hemophilia.

Authors:  C J Foley; L Nichols; K Jeong; C G Moore; M V Ragni
Journal:  J Thromb Haemost       Date:  2009-10-26       Impact factor: 5.824

7.  Evaluation of bone mineral density and related parameters in patients with haemophilia: a single center cross-sectional study.

Authors:  Hatice Demet Kiper Unal; Melda Comert Ozkan; Fatos Dilan Atilla; Zuhal Demirci; Nur Soyer; Ilgin Yildirim Simsir; Ozgur Omur; Kazim Capaci; Guray Saydam; Fahri Sahin
Journal:  Am J Blood Res       Date:  2017-11-01

8.  Atherosclerotic heart disease: prevalence and risk factors in hospitalized men with haemophilia A.

Authors:  M V Ragni; C G Moore
Journal:  Haemophilia       Date:  2011-03-04       Impact factor: 4.287

Review 9.  How I treat patients with inherited bleeding disorders who need anticoagulant therapy.

Authors:  Karlyn Martin; Nigel S Key
Journal:  Blood       Date:  2016-04-22       Impact factor: 22.113

10.  Recombinant factor VIII in the management of hemophilia A: current use and future promise.

Authors:  Jerry S Powell
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.